Extracted from this filing and checked against the source text.
Auditor Changes
SEC 8-K Item 4.01/4.02
confidence 0.9
Neuraxis, INC reported that prior financial statements should not be relied upon.
- Action
- non reliance
Exact text from the filing
On April 4, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Audit Committee of the Board and after discussion with management, concluded that the Company’s previously issued unaudited financial statements as of and for the three and nine months period ended September 30, 2023 filed with the Securities and Exchange Commission on November 20, 2023, should no longer be relied upon and should be restated due to the identification of a material accounting error.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
Neuraxis, INC reported the year ended December 31, 2023 results: revenue $2.5 million.
- Period
- the year ended December 31, 2023
- Revenue
- $2.5 million
- Result
- reported results
Exact text from the filing
medical space well, I believe we are well positioned to execute our business plan in 2024. ” Fourth Quarter and Fiscal Year 2023 Financial Results Revenue in fiscal year 2023 of $2.5 million was down 8.4% compared to $2.7 million in fiscal year 2022. The decrease was primarily due to fewer shipments to certain customers as they manage th
View on SEC.gov